Drug Discovery Platforms Market

Drug Discovery Platforms Market Overview

The global drug discovery platforms market, valued at USD 198 million in 2025, is projected to reach USD 225 million in 2026 and USD 375 million by 2030, with a 13.6% CAGR during the forecast period, 2026 to 2030.

To learn more about this report, request a free sample copy

Biologics are one of the fastest growing classes of therapeutics in the pharmaceutical industry. However, the development of such large molecule drugs is inherently complex, involving elaborate target selection and validation, hit generation, lead selection / optimization and characterization protocols. Of the aforementioned steps, hit (potential drug candidates against validated biological targets) generation is a highly resource-intensive process. In fact, it is estimated that an average of 18 months is spent in generating hits against a validated target. Additionally, there is an approximate 25% chance of failure in the hit generation to lead identification phase of drug discovery. Over time, a variety of methods / approaches have been developed for the generation of viable therapeutic leads; these include the hybridoma technology, B-cell cloning, transgenic animal-based techniques, in vitro display methods (using phages, ribosomes, mRNA, and cDNA) and cell surface display methods (involving mammalian, yeast, and bacterial cells).

Despite being responsible for the development of several successful therapies, the hybridoma and B-cell based hit generation techniques are limited in several aspects; for instance, drugs / drug candidates developed using the aforementioned technologies are often highly immunogenic, and developers also find it difficult to develop and produce stable molecules with noteworthy affinities for their respective targets. As a result, innovator companies have demonstrated a preference for some of the relatively newer hit generation methods, which involve the use of display-libraries. 

In modern medical research, display libraries have been successfully employed for the generation of various novel therapeutics and offer certain advantages over conventional drug screening methods, including (but not limited to) the ability to facilitate large-scale, high throughput screening, incorporation of greater diversity in viable lead identification, and eliminating the threat of possible immune response to pharmacological candidates identified through this approach. Out of the available display technologies, those based on phages are the most popular, primarily owing to the simplicity of the selection method they offer and the fact that they can be used to generate hits against several complex antigens. In fact, we observed that more than 15 biologics (including antibodies, proteins and peptides) that were discovered using phage display technologies, have already been approved by the USFDA; prominent examples include Humira®, Cyramza® and Benlysta®.

Further, according to various sources, around 70 display library-derived antibodies have entered clinical studies. There are many other versatile display technologies, namely yeast display, mammalian display, ribosomal display, bacterial display, mRNA display and cDNA display, which have their own benefits and have gained commendable recognition among innovators in the biopharmaceutical industry, in recent years. The growing interest in using display libraries is reflected in the recent increase in partnership activity, especially between companies that offer this technology / related services and drug developers. In summary, display technologies have enabled notable evolutionary changes in the drug discovery paradigm; we are led to believe that the drug discovery platforms market is likely to witness healthy market growth during the forecast period.

Key Companies involved in Drug Discovery Platforms Market

Examples of key companies engaged in developing display library technologies (which have also been profiled in this market report; the complete list of companies is available in the full report) include Abzena, Creative Biolabs, Distributed Bio (Subsidiary of Charles River), ImmunoPrecise Antibodies, IONTAS, LakePharma, Leading Biology, Sino Biological and XOMA. This market report includes an easily searchable excel database of all the companies providing display library technologies for drug discovery, worldwide.

Recent Developments in Drug Discovery Platforms Market:

Several recent developments have taken place in the field of drug discovery platforms market. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.

• In April 2026, Isomorphic Labs raised $2.1 billion in a Series B round with an aim to accelerate development of its unified AI drug design engine IsoDDE and advance an internal pipeline in cancer and immunology toward first clinical trials.
• In February 2026, Iambic Therapeutics entered into a collaboration with Takeda Pharmaceutical worth more than $1.7 billion in potential milestone payments. Takeda gains access to Iambic's AI-driven small-molecule discovery platform and its NeuralPLexer protein-ligand prediction model, initially targeting oncology, gastrointestinal, and inflammation programs. Iambic will also receive upfront payments plus technology access and research-cost fees.
• In January 2026, Insilico Medicine entered into drug development collaboration with Qilu Pharmaceutical for nearly $120 million, applying Insilico's generative AI Pharma.AI platform to jointly discover and develop small-molecule inhibitors for cardiometabolic diseases.
• In January 2026, Bayer collaborated with Cradle to deploy Cradle's AI protein-engineering software platform across Bayer's therapeutic antibody pipeline. Under the agreement, Bayer integrates Cradle's generative AI into its R&D workflows to enhance lead generation and optimization.

Scope of the Report

The “Drug Discovery Platforms Market: Industry Trends and Global Forecasts, till 2030” market report features an extensive study of the current market landscape, market size, market share, market forecast, market outlook and future opportunities of the drug discovery platforms market.  It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in drug discovery platforms market. In addition to other elements, the market research report features:

• A detailed assessment of the overall landscape of the display library technologies and affiliated services market, highlighting the services and technologies provided by industry players along with the information on year of establishment, company size, location of headquarters, type of company, display library expertise, type of molecules (antibodies, peptide therapeutics, proteins and others), type and format of antibodies generated, library size / complexity, and other services offered. 
• Elaborate profiles of the companies offering display library technologies. Each profile features a brief overview of the company, proprietary technology(s), recent developments and an informed future outlook.
• A case study featuring a list of biologics discovered using phage display method along with analyses, based on a number of relevant parameters, such as first launch year, target gene / antigen, disease indication and target therapeutic area, revenues generated and brief profiles.
• An analysis of the partnerships that have been established in drug discovery platforms market since 2017, covering R&D collaborations, licensing agreements, mergers and acquisitions, and other relevant deals.
• A detailed review of close to 2,000 peer-reviewed, scientific articles related to research on display libraries, which have been published since 2017. It also discusses the trends across year of publication, focus area, type of molecule, popular keywords, and key journals (in terms of number of articles published in drug discovery platforms market domain and impact factor of the journal).
• An in-depth analysis of the patents filed / granted for display library technologies, since 2017, based on the various parameters associated with the patents, including patent publication year, geographical location / patent jurisdiction, CPC symbols, emerging focus areas, and type of applicant, highlighting the leading players. In addition, it features a patent valuation analysis which evaluates the qualitative and quantitative aspects of the patents.

The key objective of drug discovery platforms market report is to provide a detailed market analysis in order to estimate the existing market size, market value, statistics and future opportunity for drug discovery platforms market during the forecast period. Based on parameters, such as size of the overall antibody and peptide discovery services market, R&D expenses incurred in hit generation step of drug discovery and several others, we have provided an informed estimate of the likely evolution of the display library services market (focus on hit generation) in the mid to long term, for the forecast period till 2030.

The market report also features the likely distribution of the opportunity across [A] type of display library technology (phage display library, yeast display and others), [B] type of molecule (antibodies, peptides and others), [C] geographical regions (North America, Europe and Asia-Pacific). In order to account for future uncertainties and to add robustness to our model, we have provided three  market forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution. 

The market report features detailed transcripts of interviews held with the following industry stakeholders:

• Andrew Bradbury (CSO / Founder, Specifica) and Ken Sharples (CEO / Founder, Specifica)
• Thomas Schirrmann (CEO / General Manager, YUMAB)
• Benjamin J. Doranz (President and CEO, Integral Molecular)
• Debby Kruijsen (General Manager, ImmunoPrecise Antibodies, Europe)

All actual figures have been sourced and analyzed from publicly available information forums. Financial figures mentioned in this market research report are in USD, unless otherwise specified.